The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1684-1695

  Wang, Jingli ^a   Foehrenbacher, Annika ^a   Su, Jiechuang ^a   Patel, Rita ^a   Hay, Michael P ^a   Hicks, Kevin O ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; ANTINEOPLASTIC AGENT; CEN 209; DNA; GAMMA HISTONE H2AX; HISTONE H2AX; OXYGEN; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; SN 30000; TIRAPAZAMINE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; AEROBIC REDUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL KILLING; CONTROLLED STUDY; COVALENT BOND; DNA DAMAGE; DRUG ACTIVATION; DRUG BINDING; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HYPERBARIC OXYGEN; HYPOXIA; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; TUMOR CELL DESTRUCTION; TUMOR CELL LINE; TUMOR HYPOXIA; TUMOR XENOGRAFT;

ANIMALS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; CYCLIC N-OXIDES; ETANIDAZOLE; FEMALE; HCT116 CELLS; HISTONES; HUMANS; HYDROCARBONS, FLUORINATED; INDICATORS AND REAGENTS; MICE; OXIDOREDUCTASES; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES;

EID: 84863229621     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2296     Document Type: Article

References (51)

1. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
2. Chang Q, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 2011;71:3110-20.
3. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009;19:106-11.
4. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120:694-705.
5. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91. (Pubitemid 26008141)
6. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature Rev Cancer 2011;11:85-95.
7. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 2007;85:139-48. (Pubitemid 46188219)
8. Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993;67:1163-70.
9. Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Exp Opinion Invest Drugs 2009;18:77-87.
10. Shinde SS, Hay MP, Patterson AV, Denny WA, Anderson RF. Spin trapping of radicals other than the*OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J Am Chem Soc 2009;131:14220-1.
11. Olive PL, Johnston PJ. DNA damage from oxidants: influence of lesion complexity and chromatin organization. Oncol Res 1997;9:287-94. (Pubitemid 127825982)
12. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 2008;68:257-65. (Pubitemid 351380127)
13. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study inHT29 multicellular layer cultures. Cancer Res 2003;63:5970-7. (Pubitemid 37187499)
14. Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98:1118-28. (Pubitemid 44288786)
15. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 2010; 16:4946-57.
16. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007;9: 1221-35. (Pubitemid 47080831)
17. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
18. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104. (Pubitemid 46622121)
19. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301-8. (Pubitemid 20214420)
20. Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18F-FAZA PET predicts success of hypoxiadirected radiochemotherapy using tirapazamine. J Nucl Med 2007; 48:973-80. (Pubitemid 46909926)
21. Minn H, Gronroos TJ, Komar G, Eskola O, Lehtio K, Tuomela J, et al. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des 2008;14:2932-42.
22. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S-48S. (Pubitemid 351948041)
23. van loon J, Janssen MHM, Ollers M, Aerts HJWL, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010;37:1663-8.
24. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsbach S, et al. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51.
25. Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, et al. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010;37:2048-59.
26. Evans SM, Du KL, Chalian AA, Mick R, Zhang PL, Hahn SM, et al. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys 2007;69:1024-31. (Pubitemid 47625842)
27. Koch CJ. Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole. Radiat Res 2008;169:677-88. (Pubitemid 351793457)
28. Patterson AV, Saunders MP, Chinje EC, Patterson LH, Stratford IJ. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des 1998;13:541-73. (Pubitemid 28410148)
29. Walton MI, Wolf CR, Workman P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine- 1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 1992;44:251-9.
30. Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc Natl Acad Sci U S A 1996; 93:456-60. (Pubitemid 26038176)
31. Guise CP, Wang A, Thiel A, Bridewell D, Wilson WR, Patterson AV. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007;74:810-20. (Pubitemid 47212075)
32. Joseph P, Jaiswal AK, Stobbe CC, Chapman JD. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int J Radiat Oncol Biol Phys 1994;29:351-5. (Pubitemid 24166545)
33. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995;72:869-74.
34. Hay MP, Gamage SA, Kovacs MS, Pruijn PB, Anderson RF, Patterson AV, et al. Structure-activity relationships of 1,2,4-benzotriazine 1,4- dioxides as hypoxia-selective analogues of tirapazamine. JMed Chem 2003;46:169-82. (Pubitemid 36043797)
35. Guise CP, Abbattista M, Singleton RS, Holford SD, Connolly J, Dachs GU, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 2010;70:1573-84.
36. Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su J, Li D, et al. Diflavin oxidoreductases activate the bioreductive prodrug PR104A under hypoxia. Mol Pharmacol 2012;81:31-40.
37. Hobbs S, Jitrapakdee S, Wallace JC. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 1998;252:368-72. (Pubitemid 28542893)
38. Chapman JD, Sturrock J, Boag JW, Crookall JO. Factors affecting the oxygen tension around cells growing in plastic petri dishes. Int J Radiat Biol 1970;17:305-28.
39. Patel K, Lewiston D, Gu Y, Hicks KO, Wilson WR. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR- 104 and its alcohol metabolite PR-104A in plasma and tissues by liquidchromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856:302-11. (Pubitemid 47302931)
40. Patterson AV, SaundersMP, Chinje EC, Talbot DC, Harris AL, Stratford IJ. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 1997;76:1338-47. (Pubitemid 27474977)
41. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that createDNAdouble-strand breaks. Cancer Res 2003;63:4347-50. (Pubitemid 36951002)
42. Olive PL, Banath JP, Sinnott LT. Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3- amino-1,2,4-benzotriazine-1,3-dioxide. Cancer Res 2004;64:5363-9. (Pubitemid 39006557)
43. Mees G, Dierckx R, Vangestel C, Van De WC. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009;36:1674-86.
44. Koch CJ, Shuman AL, Jenkins WT, Kachur AV, Karp JS, Frefeilder R, et al. The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Int J Radiat Biol 2009;85:1137-47.
45. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 1995;72:1144-50.
46. Walton MI, Wolf CR, Workman P. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 1989;16:983-6. (Pubitemid 19154286)
47. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des 1998;13:519-28. (Pubitemid 28410146)
48. Tuttle SW, Maity A, Oprysko PR, Kachur AV, Ayene IS, Biaglow JE, et al. Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration. J Biol Chem 2007;282:36790-6.
49. Siim BG, Menke DR, Dorie MJ, Brown JM. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 1997;57:2922-8. (Pubitemid 27315040)
50. 18F-EF5 microPET imaging of treatment response from a novel, hypoxia-selective cytotoxin SN30000 in a human lung cancer xenograft model. 2011 Apr 2; Philadelphia: AACR; Abstr no 5306.
51. Hunter FW, Wang J, Patel R, Hsu H-L, Hickey AJR, Hay MP, et al. Homologous recombination repair cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs. Biochem Pharmacol in press; doi 10.1016/j.bcp. 2011.12.005.